[The clinical significance of immunohaematological changes induced by penicillin and cephalosporin therapy (author's transl)].
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects*; D000918:Antibody Specificity; D002506:Cephalexin / Q000009:adverse effects; D002509:Cephaloridine / Q000009:adverse effects; D002511:Cephalosporins / Q000009:adverse effects*; D002512:Cephalothin / Q000009:adverse effects; D003298:Coombs Test; D004342:Drug Hypersensitivity / Q000097:blood; D004357:Drug Synergism; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007962:Leukocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects*; D011485:Protein Binding
D002511:Cephalosporins; D010406:Penicillins; D002509:Cephaloridine; D002506:Cephalexin; D002512:Cephalothin
Die klinische Bedeutung immunhämatologischer Veränderungen unter Behandlung mit Penicillin und Cephalosporinen.